Phase I/II study of oral immunotherapy with Cry j1 - galactomannan
Phase I/II study of oral immunotherapy with Cry j1 - galactomannan
复制标题
Cry j1 - 半乳甘露聚糖口服免疫疗法的 I/II 期研究
DOI：
10.1016/j.anl.2014.02.010
复制
发表时间：
2014
影响因子：
1.7
通讯作者：
Shizuo Komune
中科院分区：
文献类型：
--
作者：
Daisuke Murakami;Kazuhiko Kubo;Motohiro Sawatsubashi;Sayaka Kikkawa, Masayoshi Ejima;Akira Saito;Akio Kato;Shizuo Komune
在许多免疫疗法中，口服免疫疗法（OIT）被认为是对各种过敏原脱敏的有效途径。然而，很少有证据表明OIT对花粉过敏等气道过敏性疾病有效。因此，在本研究中，我们评估的安全性，有效性和免疫反应的OIT使用的哭j1-半乳甘露聚糖共轭物为日本雪松花粉allergy.MethodsAn开放试验进行了为期4个月。OIT组由23名受试者组成。在估计的花粉季节前1个月开始治疗，并持续1个月。对照组（不含OIT的药物治疗组）由11例受试者组成。的症状和药物评分，过敏原特异性血清抗体，淋巴细胞和细胞因子的产生从外周血单核细胞（PBMC）的细胞成分的水平进行了评估，在整个花粉season.ResultsThe接受OIT治疗的参与者表现出显着的改善总症状评分和非药物评分在花粉季节与对照组相比。与对照组相比，OIT组的过敏原特异性血清IgG 4和PBMC中IL-10的产生水平显著增加。重要的是，在接受OIT treatment.ConclusionShort-term OIT使用Cry j1-galactomannan共轭物是有效的，相对安全的，并诱导耐受性免疫反应，如增加过敏原特异性血清IgG 4和IL-10在PBMC中的生产。这些结果表明，OIT使用过敏原-半乳甘露聚糖共轭物可以提供一个快速，有效，安全的免疫治疗方案雪松花粉过敏。
ObjectiveAmong many immunotherapeutic approaches, oral immunotherapy (OIT) is thought to be an effective route for desensitization against a variety of allergens. However, there is little evidence that OIT is effective for airway allergic diseases such as pollen allergy. Thus, in the present study, we assessed the safety, efficacy and immune response of OIT using the Cry j1–galactomannan conjugate for Japanese cedar pollen allergy.MethodsAn open trial was conducted over a period of 4 months. The OIT group comprised of 23 subjects. Treatment was initiated 1 month before the estimated pollen season and continued for 1 month. The control group (the pharmacological treatment group without OIT) comprised of 11 subjects. The symptoms and medication score, levels of allergen-specific serum antibodies, cellular components of lymphocytes and cytokine production from peripheral blood mononuclear cells (PBMCs) were evaluated throughout the pollen season.ResultsThe participants receiving OIT treatment showed significant improvements in total symptom scores and symptom–medication scores during the pollen season compared with the control group. The levels of allergen-specific serum IgG4 and IL-10 production in PBMCs were significantly increased in the OIT group compared with that in the control group. Importantly, no severe adverse effects were observed in the participants receiving OIT treatment.ConclusionShort-term OIT using the Cry j1–galactomannan conjugate is effective, relatively safe and induces tolerant immune responses such as increased allergen-specific serum IgG4 and IL-10 production in PBMCs. These results suggest that OIT using allergen–galactomannan conjugates may provide a rapid, effective, and safe immunotherapy regimen for cedar pollen allergy.